MedCap Q4 2024: In line with profit warning, announces bolt-on deal - Redeye

Redeye provides its initial take on MedCap’s Q4 2024 report, which came in broadly below our initial estimates and in line with the company’s profit warning in mid-January. We judge that positives from the report include a continued solid financial position that leaves plenty of room for further M&A, and the company announced a bolt-on deal in connection with its report. Notable negatives include underperformance across all segments, though we judge some one-off factors led to numbers looking worse than what we can expect in coming quarters.

Länk till analysen i sin helhet: https://www.redeye.se/research/1071387/medcap-q4-2024-in-line-with-profit-warning-announces-bolt-on-deal?utm_source=finwire&utm_medium=RSS